Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay is well-positioned for future growth as enterprise behavioral health adoption and provider ROI continue to drive demand for their Deep TMS technology, particularly with the recent introduction of the SWIFT protocol. Furthermore, their shift towards a recurring-revenue model and strong financials, including a large cash balance and expected doubling of bottom-line results in 2026, provide solid support for continued organic investment and commercial execution. Despite risks to price target achievement, including slower uptake and expansion into new indications, the sales multiple-driven approach yields a 12-month price target of $17 per share, with a total firm value of ~$730M.

Bears say

BrainsWay is a leader in the field of advanced noninvasive neurostimulation treatments for mental health disorders, but its financial outlook is concerning. Despite its strong competitive position and extensive infrastructure, the company has struggled to generate significant revenues and maintain profitability. Additionally, as a result of Valor Equity Partners' significantly stronger financial position following the SpaceX IPO, BrainsWay's support and investments from this key long-term investor may diminish or shift towards other companies, potentially impacting the company's growth prospects.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.